Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403661 | 0.80 | AVPR1A (0.40) | SIGMAR1NPY5RGRIN2DGRIN3BCHRM2 | |
| SCHEMBL13015175 | 0.78 | GRIN2D (0.38) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL12219041 | 0.78 | SIGMAR1 (0.42) | SIGMAR1NPY5RGRIN2DGRIN3BCHRM2 | |
| SCHEMBL12219040 | 0.75 | SIGMAR1 (0.42) | SIGMAR1NPY5RGRIN2DGRIN3BCHRM2 | |
| SCHEMBL13015170 | 0.75 | SIGMAR1 (0.34) | SIGMAR1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL15935552 | 0.71 | DGAT1 (0.30) | — | |
| SCHEMBL12219039 | 0.71 | SIGMAR1 (0.61) | SIGMAR1NPY5RGRIN2DGRIN3BCHRM2 | |
| SCHEMBL12219042 | 0.68 | AVPR1A (0.41) | SIGMAR1NPY5RGRIN2DGRIN3BCHRM2 | |
| SCHEMBL8110392 | 0.63 | SIGMAR1 (0.58) | SIGMAR1NPY5R | |
| SCHEMBL13342755 | 0.62 | KCNH2 (0.52) | NPY5RGRIN2DGRIN3BCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | SIGMAR1 562/4885NPY5R 51/4885GRIN2D 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.